These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 25929949)

  • 1. Oral vasopressin receptor antagonist tolvaptan in right heart failure due to pulmonary hypertension.
    Tamura Y; Kimura M; Takei M; Ono T; Kuwana M; Satoh T; Fukuda K; Humbert M
    Eur Respir J; 2015 Jul; 46(1):283-6. PubMed ID: 25929949
    [No Abstract]   [Full Text] [Related]  

  • 2. [Effectiveness of tolvaptan for postoperative heart failure in a patient with combined valvular disease and pulmonary hypertension].
    Kondo T; Hoshino J; Fukada Y; Hirota M; Takahashi Y; Isomura T
    Kyobu Geka; 2014 Feb; 67(2):117-20. PubMed ID: 24743480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of tolvaptan in patients with hyponatremia due to heart failure: initial experience.
    Rodríguez-de Muñoz YM; Sánchez-Lázaro IJ; Almenar-Bonet L; Martínez-Dolz L; Rodríguez-Serrano M; Salvador-Sanz A
    Rev Esp Cardiol (Engl Ed); 2013 Apr; 66(4):319-21. PubMed ID: 24775629
    [No Abstract]   [Full Text] [Related]  

  • 4. Response Prediction and Influence of Tolvaptan in Chronic Heart Failure Patients Considering the Interaction of the Renin-Angiotensin-Aldosterone System and Arginine Vasopressin.
    Kadota M; Ise T; Yagi S; Iwase T; Akaike M; Ueno R; Kawabata Y; Hara T; Ogasawara K; Bando M; Bando S; Matsuura T; Yamaguchi K; Yamada H; Soeki T; Wakatsuki T; Sata M
    Int Heart J; 2016 Jul; 57(4):461-5. PubMed ID: 27357439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and adverse events of tolvaptan in octogenarians with heart failure. Interim analyses of Samsca Post-Marketing Surveillance In Heart faiLurE (SMILE study).
    Kinugawa K; Inomata T; Sato N; Yasuda M; Shimakawa T; Bando K; Mizuguchi K
    Int Heart J; 2015; 56(2):137-43. PubMed ID: 25740389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasopressin V2 receptor antagonist tolvaptan is effective in heart failure patients with reduced left ventricular systolic function and low blood pressure.
    Suzuki S; Yoshihisa A; Yamaki T; Sugimoto K; Kunii H; Nakazato K; Abe Y; Saito T; Ohwada T; Suzuki H; Saitoh S; Kubota I; Takeishi Y;
    Int Heart J; 2015; 56(2):213-8. PubMed ID: 25740399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of tolvaptan on congestive heart failure complicated with chylothorax in a neonate.
    Sato N; Sugiura T; Nagasaki R; Suzuki K; Ito K; Kato T; Inukai S; Saitoh S
    Pediatr Int; 2015 Oct; 57(5):1020-2. PubMed ID: 26508187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of tolvaptan in patients hospitalized for heart failure with refractory hyponatremia. Clinical experience in daily practice.
    Salterain-Gonzalez N; Esteban-Fernández A; García-López M; Lavilla-Royo FJ; Gavira-Gómez JJ
    Rev Esp Cardiol (Engl Ed); 2013 Jun; 66(6):503-4. PubMed ID: 24776057
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of Tolvaptan Addition to Furosemide in Normo- and Hyponatremia Patients with Heart Failure and Chronic Kidney Disease Stages G3b-5: A Subanalysis of the K-STAR Study.
    Tominaga N; Kida K; Inomata T; Sato N; Izumi T; Akashi YJ; Shibagaki Y
    Am J Nephrol; 2017; 46(5):417-426. PubMed ID: 29130954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood urea nitrogen as a marker of the acute response to addition of tolvaptan to standard therapy in patients hospitalized for acute heart failure syndromes.
    Kajimoto K; Abe T
    Int J Cardiol; 2014 Dec; 177(2):589-91. PubMed ID: 25200849
    [No Abstract]   [Full Text] [Related]  

  • 11. Aquaporin-2 is a potential biomarker for tolvaptan efficacy in decompensated heart failure complicated by diabetic nephrotic syndrome.
    Tanaka A; Nakamura T; Sato E; Node K
    Int J Cardiol; 2016 May; 210():1-3. PubMed ID: 26921537
    [No Abstract]   [Full Text] [Related]  

  • 12. Tolvaptan alleviates excessive fluid retention of nephrotic diabetic renal failure unresponsive to furosemide.
    Takada T; Masaki T; Hoshiyama A; Toki T; Kamata Y; Shichiri M
    Nephrology (Carlton); 2018 Sep; 23(9):883-886. PubMed ID: 29665203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urine Aquaporin-2: A Promising Marker of Response to the Arginine Vasopressin Type-2 Antagonist, Tolvaptan in Patients with Congestive Heart Failure.
    Imamura T; Kinugawa K
    Int J Mol Sci; 2016 Jan; 17(1):. PubMed ID: 26784173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical characteristics of responders to treatment with tolvaptan in patients with acute decompensated heart failure: Importance of preserved kidney size.
    Toda H; Nakamura K; Nakahama M; Wada T; Watanabe A; Hashimoto K; Terasaka R; Tokioka K; Nishii N; Miyoshi T; Kohno K; Kawai Y; Miyaji K; Koide Y; Tachibana M; Yoshioka R; Ito H;
    J Cardiol; 2016 Feb; 67(2):177-83. PubMed ID: 26072263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re-response to tolvaptan after furosemide dose reduction in a patient with refractory ascites.
    Goto A; Terai S; Nakamura M; Matsumoto M; Sakaida I
    Clin J Gastroenterol; 2015 Feb; 8(1):47-51. PubMed ID: 25475138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of tolvaptan for pediatric patients with congestive heart failure. Multicenter survey in the working group of the Japanese Society of PEdiatric Circulation and Hemodynamics (J-SPECH).
    Higashi K; Murakami T; Ishikawa Y; Itoi T; Ohuchi H; Kodama Y; Honda T; Masutani S; Yamazawa H; Senzaki H; Ishikawa S
    Int J Cardiol; 2016 Feb; 205():37-42. PubMed ID: 26710331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful Treatment of Severe Right-Sided Heart Failure Due to Postoperative Constrictive Pericarditis With Tolvaptan.
    Kanaya M; Matsushita K; Inami T; Yamasaki S; Mizumi S; Minamishima T; Goda A; Ueda A; Sakata K; Satoh T; Yoshino H
    Am J Ther; 2016; 23(1):e264-7. PubMed ID: 25343308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ratio of urine and blood urea nitrogen concentration predicts the response of tolvaptan in congestive heart failure.
    Shimizu K; Doi K; Imamura T; Noiri E; Yahagi N; Nangaku M; Kinugawa K
    Nephrology (Carlton); 2015 Jun; 20(6):405-12. PubMed ID: 25619790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Tolvaptan in Patients Hospitalized With Acute Heart Failure.
    Felker GM; Mentz RJ; Cole RT; Adams KF; Egnaczyk GF; Fiuzat M; Patel CB; Echols M; Khouri MG; Tauras JM; Gupta D; Monds P; Roberts R; O'Connor CM
    J Am Coll Cardiol; 2017 Mar; 69(11):1399-1406. PubMed ID: 27654854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical effectiveness of tolvaptan in patients with acute decompensated heart failure and renal failure: design and rationale of the AQUAMARINE study.
    Matsue Y; Suzuki M; Nagahori W; Yoshida K; Onishi Y; Satoh Y; Ono Y; Nishioka T; Noda M; Sugi K; Torii S; Tejima T; Sakurada H; Yamaguchi S; Okishige K; Fujii H; Takahashi A
    Cardiovasc Drugs Ther; 2014 Feb; 28(1):73-7. PubMed ID: 24048511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.